Advertisement

Cardiovascular Outcome Trials and Expert Consensus Decision Pathways: Interpreting the Evidence with Nonstatin Therapies

Step 1
Register
Step 2
Pre-Test
Step 3
Video
Step 4
Post Test
Step 5
Evaluation
Step 6
Certificate
OBJECTIVES & ACCREDITATION

RELEASE DATE: November 1, 2018

EXPIRATION DATE: November 1, 2019

PROGRAM OVERVIEW
The ongoing presentation of evidence from the IMPROVE-IT and FOURIER trials has created a need for lipidologists to be informed of this information which may have a significant impact on their practice. Furthermore, an assessment of the ODYSSEY OUTCOMES trial, and a comparison/contrast of the FOURIER and ODYSSEY OUTCOMES trials are needed to assist lipidologists with clinical decision-making regarding prudent use of PCSK9 inhibitors. Best practice is rapidly evolving with non-statin therapies, necessitating the release of updated recommendations. In this program, Drs. Giugliano, Ballantyne, Brinton, Saseen, and Toth will analyze landmark trials with non-statin therapies and provide recommendations for practice.

ACTIVITY TYPE
Enduring Internet Activity

TARGET AUDIENCE
This activity is designed to meet the needs of lipidologists, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.

LEARNING OBJECTIVES
At the Conclusion of this activity, participants should be able to:

  • Compare and contrast cardiovascular outcome trials with PCSK9 inhibitors.
  • Discuss secondary analyses from cardiovascular outcome trials with non-statin therapies.
  • Explain recommendations in the 2017 Focused Update and the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk.
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS
A statement of credit will be available upon completion of an online evaluation/claimed credit form. The deadline to claim credit is November 1, 2019. If you have any questions regarding the CME/CE credit, please contact cme@lipid.org.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

COMMERCIAL SUPPORT
This activity is supported by an educational grant from Amgen.

CREDIT DESIGNATION
CME credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and VoxMedia. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.

Pharmacist Accreditation Statement

Universal Activity Number – JA0007192-9999-18-029-H01-P (Knowledge)
This Activity has been approved for 2 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 2.0 contact hours.

CHAIR

Robert Giugliano, MD, SM
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

FACULTY
Christie Ballantyne, MD
Professor of Medicine
Chief, Section of Cardiology
Baylor College of Medicine
Houston, Texas
Joseph Saseen, PharmD
Professor and Vice Chair
Department of Clinical Pharmacy
Professor, Department of Family Medicine
University of Colorado
Anschutz Medical Campus
Aurora, Colorado
Eliot Brinton, MD
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, Utah
Peter Toth, MD, PhD
Professor
Clinical Family
and Community Medicine
University of Illinois School of Medicine
Peoria, Illinois

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

FACULTY/PLANNER FINANCIAL DISCLOSURES
Name Relationship Company
Ballantyne, Christie Consultant Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck & Co., Inc., Novartis Pharmaceuticals, Regeneron, Sanofi-Synthelabo
Contracted Research Abbott Diagnostics, Amarin, Amgen, Esperion, Ionis, Novartis Pharmaceuticals, Pfizer, Regeneron, Roche Diagnostics, Sanofi-Synthelabo
Brinton, Eliot Consultant Akcea, Amarin, Amgen, Balchem, Kastle, Kowa, Merck & Co., Inc., PTS Diagnostics, Regeneron, Sanofi
Contracted Research Amarin, Kowa
Speaker Akcea, Amarin, Amgen, Boehringer Ingelheim, Kastle, Kowa, Merck & Co., Inc., Novo Nordisk, Regeneron, Sanofi
Morris, Pamela Consultant Amgen Inc., Esperion, Regeneron and Sanofi
Contracted Research Amgen Inc., Esperion
Giugliano, Robert Consultant Amarin, Amgen, Boehringer- Ingelheim, Bristol-Myers-Squibb, CVS Caremark, Daiichi-Sankyo, GlaxoSmithKline, Lexicon, Merck & Co., Inc., Portola, Pfizer
Contracted Research Amgen
Speaker Amgen, Daiichi-Sankyo, Merck & Co., Inc.
Saseen, Joseph N/A Has nothing to disclose.
Toth, Peter Consultant Akcea Therapeutics, Amarin Corporation, Amgen Inc., KOWA Pharmaceuticals America, Inc., Merck & Co., Inc., Novo Nordisk, Regeneron Pharmaceuticals, Inc.
Contracted Research Amarin Corporation, Amgen Inc., KOWA Pharmaceuticals America, Inc., Merck & Co., Inc., Novo Nordisk, Regeneron Pharmaceuticals, Inc., Sanofi
STAFF/ REVIEWER DISCLOSURES
NLA N/A NLA staff has nothing to disclose.
Halli Demeter, Susan N/A Has nothing to disclose.

0
No votes yet
Publish Date: 
Thursday, October 25, 2018 - 13:45

This page was last updated: Jun 06, 2019

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service